These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 16930812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 3. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [Abstract] [Full Text] [Related]

  • 4. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 5. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH.
    Cancer; 2006 Dec 15; 107(12):2779-85. PubMed ID: 17109445
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul 15; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 8. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S, Roobol MJ, Gosselaar C, Schröder FH.
    Prostate; 2006 Jul 01; 66(10):1076-81. PubMed ID: 16637077
    [Abstract] [Full Text] [Related]

  • 9. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [Abstract] [Full Text] [Related]

  • 10. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
    Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schröder FH.
    Eur Urol; 2007 May 01; 51(5):1244-50; discussion 1251. PubMed ID: 17161520
    [Abstract] [Full Text] [Related]

  • 11. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH.
    Urol Oncol; 2008 May 01; 26(5):533-41. PubMed ID: 18774469
    [Abstract] [Full Text] [Related]

  • 12. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ, Grenabo A, Schröder FH, Hugosson J.
    J Natl Cancer Inst; 2007 Sep 05; 99(17):1296-303. PubMed ID: 17728218
    [Abstract] [Full Text] [Related]

  • 13. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.
    Eur Urol; 2012 Jan 05; 61(1):171-6. PubMed ID: 21840117
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ.
    Urol Oncol; 2006 Jan 05; 24(6):465-71. PubMed ID: 17138126
    [Abstract] [Full Text] [Related]

  • 17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 05; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 18. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study.
    Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O.
    Eur Urol; 2008 Jan 05; 53(1):106-11. PubMed ID: 17482753
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumour features in the control and screening arm of a randomized trial of prostate cancer.
    Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH.
    Eur Urol; 2006 Jul 05; 50(1):70-5. PubMed ID: 16434136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.